JP7884019B2 - Ｉｄｈ変異体阻害剤およびその使用 - Google Patents

Ｉｄｈ変異体阻害剤およびその使用

Info

Publication number
JP7884019B2
JP7884019B2 JP2023577688A JP2023577688A JP7884019B2 JP 7884019 B2 JP7884019 B2 JP 7884019B2 JP 2023577688 A JP2023577688 A JP 2023577688A JP 2023577688 A JP2023577688 A JP 2023577688A JP 7884019 B2 JP7884019 B2 JP 7884019B2
Authority
JP
Japan
Prior art keywords
compound
compounds
pharmaceutically acceptable
general formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023577688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524933A (ja
JP2024524933A5 (enExample
Inventor
シエ，ユリ
ファン，ホウシン
チエン，リフゥイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of JP2024524933A publication Critical patent/JP2024524933A/ja
Publication of JP2024524933A5 publication Critical patent/JP2024524933A5/ja
Application granted granted Critical
Publication of JP7884019B2 publication Critical patent/JP7884019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023577688A 2021-06-15 2022-06-15 Ｉｄｈ変異体阻害剤およびその使用 Active JP7884019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110661394.5 2021-06-15
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (3)

Publication Number Publication Date
JP2024524933A JP2024524933A (ja) 2024-07-09
JP2024524933A5 JP2024524933A5 (enExample) 2025-06-23
JP7884019B2 true JP7884019B2 (ja) 2026-07-02

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577688A Active JP7884019B2 (ja) 2021-06-15 2022-06-15 Ｉｄｈ変異体阻害剤およびその使用

Country Status (10)

Country Link
US (1) US20240208978A1 (enExample)
EP (1) EP4356914A4 (enExample)
JP (1) JP7884019B2 (enExample)
KR (1) KR20240021774A (enExample)
CN (1) CN117460512A (enExample)
AU (1) AU2022294860A1 (enExample)
BR (1) BR112023024454A2 (enExample)
CA (1) CA3217608A1 (enExample)
MX (1) MX2023013664A (enExample)
WO (1) WO2022262784A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP2018525369A (ja) 2015-07-27 2018-09-06 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
SMT202200255T1 (it) * 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
JP6682043B2 (ja) 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
JP6793836B2 (ja) * 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP2018525369A (ja) 2015-07-27 2018-09-06 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
EP4356914A1 (en) 2024-04-24
CA3217608A1 (en) 2022-12-22
BR112023024454A2 (pt) 2024-02-06
AU2022294860A1 (en) 2024-01-25
MX2023013664A (es) 2024-01-08
KR20240021774A (ko) 2024-02-19
EP4356914A4 (en) 2025-01-08
US20240208978A1 (en) 2024-06-27
JP2024524933A (ja) 2024-07-09
WO2022262784A1 (zh) 2022-12-22
CN117460512A (zh) 2024-01-26

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260622

R150 Certificate of patent or registration of utility model

Ref document number: 7884019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150